NASDAQ:AERI Aerie Pharmaceuticals - AERI Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice Target$16.90 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Aerie Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside10.8% Upside$16.90 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.26Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.02) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.51 out of 5 starsMedical Sector949th out of 1,030 stocksBiological Products, Except Diagnostic Industry156th out of 169 stocks 2.0 Analyst's Opinion Consensus RatingAerie Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.90, Aerie Pharmaceuticals has a forecasted upside of 10.8% from its current price of $15.25.Amount of Analyst CoverageAerie Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AERI. Previous Next 0.0 Dividend Strength Dividend YieldAerie Pharmaceuticals does not currently pay a dividend.Dividend GrowthAerie Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAerie Pharmaceuticals has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Netarsudil", "Latanoprost", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Aerie Pharmaceuticals is -2.26. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for AERI on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerie Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.44% of the stock of Aerie Pharmaceuticals is held by insiders.Percentage Held by Institutions95.94% of the stock of Aerie Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($2.02) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aerie Pharmaceuticals (NASDAQ:AERI) StockAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AERI Stock News HeadlinesJanuary 4, 2023 | marketwatch.comGlaucoma Therapeutics Market High Growth Opportunities 2023 | CAGR Status, Industry Changing Dynamics, and Size Forecast to 2027November 16, 2022 | seekingalpha.comAlcon Inc. (ALC) Q3 2022 Earnings Call TranscriptFebruary 2, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.November 4, 2022 | apnews.comAerie Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 1, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, SMBC, EVOPOctober 17, 2022 | finance.yahoo.comAre Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?October 14, 2022 | marketwatch.comOphthalmic Products Market Size and Share Research 2022 Key Dynamics, Leading Companies, Business Developments and Demand Forecast 2030September 29, 2022 | finance.yahoo.comIs Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! September 28, 2022 | finance.yahoo.comAerie Pharmaceuticals, Inc. (AERI)September 20, 2022 | finance.yahoo.comAurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European ApprovalSeptember 20, 2022 | finance.yahoo.comHere Are 10 Biotech Stocks That Would Have Netted You $12,000 This YearSeptember 19, 2022 | finance.yahoo.comHere Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This YearSeptember 13, 2022 | finance.yahoo.comRegulus (RGLS) Up on Top-Line Data from Kidney Disease StudySeptember 13, 2022 | finance.yahoo.comAerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment OptionsSeptember 1, 2022 | finance.yahoo.comImmunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer CandidateAugust 31, 2022 | finance.yahoo.comAerie (AERI) Rallies 205.6% in the Past Three Months: Here's WhyAugust 26, 2022 | finance.yahoo.comHas Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?August 26, 2022 | finance.yahoo.comWhy Aerie Pharmaceuticals Was Soaring So High This WeekAugust 24, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Aerie Pharmaceuticals, Inc. – AERIAugust 24, 2022 | marketwatch.comAerie Pharmaceuticals Shares Rise 34% After Alcon Buyout OfferAugust 24, 2022 | msn.comAerie Pharmaceuticals's Return On Capital Employed OverviewAugust 24, 2022 | nasdaq.comDid You Buy Signify Health And Aerie Pharma Shares?August 23, 2022 | finance.yahoo.comAlcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma PortfolioAugust 23, 2022 | finance.yahoo.comAlcon May Struggle To Meet 2023 Margin Targets With This Latest Acquisition, Says This AnalystAugust 23, 2022 | finance.yahoo.comAerie set to be bought by Alcon for $770 millionAugust 23, 2022 | finance.yahoo.comBlistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 MillionSee More Headlines Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AERI Company Calendar Last Earnings11/04/2021Today2/02/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AERI CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.90 High Stock Price Forecast$25.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+10.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,810,000.00 Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 Key ExecutivesMr. Raj Kannan (Age 58)CEO, Principal Financial Officer & Director Comp: $753.49kDr. Casey C. Kopczynski Ph.D. (Age 61)Co-Founder, Chief Innovation Officer & Head of Research and External Innovation Comp: $685.06kMr. John W. LaRocca Esq. (Age 57)Gen. Counsel & Sec. Comp: $676.62kMr. Peter F. Lang (Age 50)Chief Financial Officer Dr. Michelle Senchyna Ph.D.Head of Clinical Devel. & OperationsMr. Jeffrey M. Calabrese CPA (Age 55)VP of Fin. & Principal Accounting Officer Ms. Carolyn McAuliffeSr. Director of CommunicationsMs. Wanda FranciesHead of HRMr. Marvin J. Garrett (Age 71)Head of Regulatory Affairs & Quality Assurance Mr. Craig R. SkenesHead of Bus. Devel.More ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSADMA BiologicsNASDAQ:ADMAAlectorNASDAQ:ALECAgenusNASDAQ:AGENEditas MedicineNASDAQ:EDITView All CompetitorsInsiders & InstitutionsEquitec Proprietary Markets LLCSold 5,000 shares on 1/31/2023Ownership: 0.000%Bank of New York Mellon CorpBought 10,405 shares on 12/8/2022Ownership: 0.483%California State Teachers Retirement SystemSold 1,179 shares on 11/21/2022Ownership: 0.114%Fred Alger Management LLCSold 461,240 shares on 11/16/2022Ownership: 1.211%BNP Paribas Arbitrage SNCBought 6,362 shares on 11/16/2022Ownership: 0.034%View All Institutional Transactions AERI Stock - Frequently Asked Questions Should I buy or sell Aerie Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AERI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AERI, but not buy additional shares or sell existing shares. View AERI analyst ratings or view top-rated stocks. What is Aerie Pharmaceuticals' stock price forecast for 2023? 6 brokerages have issued 12-month price objectives for Aerie Pharmaceuticals' stock. Their AERI share price forecasts range from $14.00 to $25.00. On average, they expect the company's stock price to reach $16.90 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View analysts price targets for AERI or view top-rated stocks among Wall Street analysts. When is Aerie Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our AERI earnings forecast. How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The business earned $29.31 million during the quarter, compared to analysts' expectations of $29.13 million. During the same period last year, the business earned ($0.65) EPS. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA). What is Aerie Pharmaceuticals' stock symbol? Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI." Who are Aerie Pharmaceuticals' major shareholders? Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Casey C Kopczynski and Gerald D Cagle. View institutional ownership trends. What is Aerie Pharmaceuticals' stock price today? One share of AERI stock can currently be purchased for approximately $15.25. How much money does Aerie Pharmaceuticals make? Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $753.61 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How many employees does Aerie Pharmaceuticals have? The company employs 376 workers across the globe. How can I contact Aerie Pharmaceuticals? Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787. This page (NASDAQ:AERI) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.